Novo Nordisk Gets Settlements to Stop Sales of Unapproved Semaglutide

Novo Nordisk achieved settlements that force two clinics to cease selling unapproved versions of the company’s semaglutide products and explain in their marketing materials that unapproved compounded drugs have not been evaluated or approved by the FDA.

Novo brought the action against these two Florida clinics — Nuvida Rx Weight Loss in Tallahassee and Cosmetic Laser Professionals Med Spa in Miami — for “trademark infringement, false advertising, and unfair competition, according to both settlements.

Novo Nordisk has brought similar suits against other clinics selling unapproved semaglutide products across four states in July 2023. Novo owns the trademark registrations for Ozempic, Wegovy and Rybelsus, and the settlements explain that the clinics falsely suggested the unapproved compounded drugs they sold are genuine Novo Nordisk products.

Read the Cosmetic Laser Professionals Med Spa judgment here.

Read the Nuvida Rx Weight Loss judgment here.

To read the whole story, click here to subscribe.

Related Topics